Cargando…

Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo

Background and Objects: Bruton's tyrosine kinase inhibitors are commonly used and effective for lymphoma and chronic lymphocytic leukemia (CLL). Ibrutinib might improve the effect of anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CD19 CAR) T-cell therapy in lymphoma, but t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Xiupeng, Liu, Meijing, Lv, Cuicui, Li, Yeqiong, Chen, Lan, Zhang, Jin, Mu, Juan, Deng, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580088/
https://www.ncbi.nlm.nih.gov/pubmed/36254554
http://dx.doi.org/10.1177/15330338221133224
_version_ 1784812317885595648
author Ye, Xiupeng
Liu, Meijing
Lv, Cuicui
Li, Yeqiong
Chen, Lan
Zhang, Jin
Mu, Juan
Deng, Qi
author_facet Ye, Xiupeng
Liu, Meijing
Lv, Cuicui
Li, Yeqiong
Chen, Lan
Zhang, Jin
Mu, Juan
Deng, Qi
author_sort Ye, Xiupeng
collection PubMed
description Background and Objects: Bruton's tyrosine kinase inhibitors are commonly used and effective for lymphoma and chronic lymphocytic leukemia (CLL). Ibrutinib might improve the effect of anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CD19 CAR) T-cell therapy in lymphoma, but the effects of zanubrutinib combined with CAR-T cells is unclear. Methods: We selected a low effect-target ratio (E:T = 1:3) to study this synergistic effect in vitro. The programed cell death protein 1 (PD-1) expression in CD19 CAR-T cells and immune phenotype of T lymphocytes were analyzed by flow cytometry (FCM). We selected CD19 CAR-T cells of a patient with diffuse large B cell lymphoma (DLBCL) to study the synergistic effect of zanubrutinib with CAR-T cells by bioluminescence imaging monitoring. The CD19 CAR-T cells expansion in mice was compared by FCM. Results: Zanubrutinib and ibrutinib had dose-dependent toxicity on both CAR-T cells and lymphoma cells. But there was no significant synergistic effect of the CD19 CAR-T cells combined with zanubrutinib/ibrutinib in vitro. The PD-1 expression in CD19 CAR-T cells increased when the CD19 CAR-T cells were co-cultured with Raji cells and decreased when ibrutinib was added in culture, but zanubrutinib had no such effect. The extinction of luciferase expression was more obvious in the polytherapy group of ibrutinib and CD19 CAR-T cell than that in the other groups. Moreover, the proportion of CAR-T cells in the combination therapy group of CD19 CAR-T cells and ibrutinib was higher than that of the polytherapy group of CD19 CAR-T cells with zanubrutinib group. The synergistic effect could be observed obviously in mice receiving ibrutinib combined with CD19 CAR-T cells. But zanubrutinib cannot perform joint therapy effect either in vitro or in mice. Conclusion: Zanubrutinib might have no joint therapy effect with CD19 CAR-T cells neither in vitro nor in mice, but the mechanism of different curative effects requires our further research and exploration.
format Online
Article
Text
id pubmed-9580088
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-95800882022-10-20 Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo Ye, Xiupeng Liu, Meijing Lv, Cuicui Li, Yeqiong Chen, Lan Zhang, Jin Mu, Juan Deng, Qi Technol Cancer Res Treat Original Article Background and Objects: Bruton's tyrosine kinase inhibitors are commonly used and effective for lymphoma and chronic lymphocytic leukemia (CLL). Ibrutinib might improve the effect of anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CD19 CAR) T-cell therapy in lymphoma, but the effects of zanubrutinib combined with CAR-T cells is unclear. Methods: We selected a low effect-target ratio (E:T = 1:3) to study this synergistic effect in vitro. The programed cell death protein 1 (PD-1) expression in CD19 CAR-T cells and immune phenotype of T lymphocytes were analyzed by flow cytometry (FCM). We selected CD19 CAR-T cells of a patient with diffuse large B cell lymphoma (DLBCL) to study the synergistic effect of zanubrutinib with CAR-T cells by bioluminescence imaging monitoring. The CD19 CAR-T cells expansion in mice was compared by FCM. Results: Zanubrutinib and ibrutinib had dose-dependent toxicity on both CAR-T cells and lymphoma cells. But there was no significant synergistic effect of the CD19 CAR-T cells combined with zanubrutinib/ibrutinib in vitro. The PD-1 expression in CD19 CAR-T cells increased when the CD19 CAR-T cells were co-cultured with Raji cells and decreased when ibrutinib was added in culture, but zanubrutinib had no such effect. The extinction of luciferase expression was more obvious in the polytherapy group of ibrutinib and CD19 CAR-T cell than that in the other groups. Moreover, the proportion of CAR-T cells in the combination therapy group of CD19 CAR-T cells and ibrutinib was higher than that of the polytherapy group of CD19 CAR-T cells with zanubrutinib group. The synergistic effect could be observed obviously in mice receiving ibrutinib combined with CD19 CAR-T cells. But zanubrutinib cannot perform joint therapy effect either in vitro or in mice. Conclusion: Zanubrutinib might have no joint therapy effect with CD19 CAR-T cells neither in vitro nor in mice, but the mechanism of different curative effects requires our further research and exploration. SAGE Publications 2022-10-18 /pmc/articles/PMC9580088/ /pubmed/36254554 http://dx.doi.org/10.1177/15330338221133224 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Ye, Xiupeng
Liu, Meijing
Lv, Cuicui
Li, Yeqiong
Chen, Lan
Zhang, Jin
Mu, Juan
Deng, Qi
Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo
title Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo
title_full Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo
title_fullStr Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo
title_full_unstemmed Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo
title_short Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo
title_sort synergistic effects of zanubrutinib combined with cd19 car-t cells in raji cells in vitro and in vivo
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580088/
https://www.ncbi.nlm.nih.gov/pubmed/36254554
http://dx.doi.org/10.1177/15330338221133224
work_keys_str_mv AT yexiupeng synergisticeffectsofzanubrutinibcombinedwithcd19cartcellsinrajicellsinvitroandinvivo
AT liumeijing synergisticeffectsofzanubrutinibcombinedwithcd19cartcellsinrajicellsinvitroandinvivo
AT lvcuicui synergisticeffectsofzanubrutinibcombinedwithcd19cartcellsinrajicellsinvitroandinvivo
AT liyeqiong synergisticeffectsofzanubrutinibcombinedwithcd19cartcellsinrajicellsinvitroandinvivo
AT chenlan synergisticeffectsofzanubrutinibcombinedwithcd19cartcellsinrajicellsinvitroandinvivo
AT zhangjin synergisticeffectsofzanubrutinibcombinedwithcd19cartcellsinrajicellsinvitroandinvivo
AT mujuan synergisticeffectsofzanubrutinibcombinedwithcd19cartcellsinrajicellsinvitroandinvivo
AT dengqi synergisticeffectsofzanubrutinibcombinedwithcd19cartcellsinrajicellsinvitroandinvivo